Santi Therapeutics

The company's core focus is on designing and discovering molecular glues, which are small molecules engineered to induce or stabilize interactions between proteins. This technology aims to alter the function or fate of a disease-related target protein, opening up avenues for therapeutic intervention across a variety of diseases. The business model is centered on the research and development of these small molecule therapeutics, with the goal of advancing them through the clinical pipeline. The company operates within the drug discovery and development sector of the pharmaceutical industry.

Santi Therapeutics' strategic direction shifted when it began operating as TRIANA Biomedicines. This transition was marked by significant financial milestones, including an Early Stage VC round in September 2021, followed by a substantial $110 million Series A venture capital financing in April 2022. This capital infusion is intended to accelerate product development and expand the company's operational capacity.

The firm's platform is built to rationally design these molecular glues for high-value disease targets that have been traditionally difficult to address with conventional drug modalities. By creating novel interactions between proteins or stabilizing existing ones, their approach has the potential to address a wide range of therapeutic areas. The President, Milind Deshpande, was instrumental in securing investments to drive this expansion and accelerate the development of their therapeutic candidates.